Viking Therapeutics announced it will present two posters at the 33rd European Congress on Obesity highlighting data from its Phase 2 trial of VK2735, an oral and subcutaneous dual GLP-1/GIP receptor agonist for obesity treatment. The Phase 2 VENTURE-Oral trial showed significant weight loss and good tolerability over 13 weeks. Additionally, Viking shared enrollment details of the ongoing Phase 3 VANQUISH-1 trial targeting adults with obesity or overweight with related health issues. These presentations mark important steps in VK2735's clinical development, with further data expected from the Phase 3 study.
Sierra Bancorp reported Q2 earnings per share (EPS) of $0.77, below analyst expectations of $0.89, and revenue of $38.98 million, missing the forecast of $39.59 million. The EPS slightly declined from $0.78 a year ago, indicating a small year-over-ye...
Navitas Semiconductor, a maker of AI data center power chips, has seen its stock fall 40% this month, making its upcoming earnings report crucial. Analysts expect a loss of $0.04 per share and revenue near $10 million, reflecting a 31.3% decline from...
Michelin has published its financial report for the first half of 2026, which is now accessible on its official website. The report has also been officially filed with the French Autorité des Marchés Financiers (AMF), ensuring regulatory compliance. ...
Michelin has published and filed its half-year financial report as of June 30, 2026, with the French financial regulator AMF. The report and the presentation of the 2026 half-year results are accessible on Michelin's official website. This disclosure...
In the first half of 2026, Michelin saw an increase in segment operating income at constant scope and exchange rates, alongside a rise in free cash flow before mergers and acquisitions. The company has confirmed its financial guidance for the full ye...
